Jerome Cornillon

Saint-etienne-de-valoux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)

Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)

Journal: Bulletin du cancer

Published: January 28, 2026

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Journal: Bone marrow transplantation

Published: December 11, 2025

Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure.

Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure.

Journal: Bone marrow transplantation

Published: December 01, 2025

Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.

Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.

Journal: Blood advances

Published: October 27, 2025

Effect of Deferasirox Six Months after allo-HSCT on AML/MDS Outcomes: a Propensity-Score Matched Study.

Effect of Deferasirox Six Months after allo-HSCT on AML/MDS Outcomes: a Propensity-Score Matched Study.

Journal: Blood advances

Published: October 27, 2025

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Journal: Leukemia

Published: October 25, 2025

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Journal: Bone marrow transplantation

Published: October 01, 2025

Thromboelastometric assessment of the haemostatic effect of tranexamic acid as an adjunct to prophylactic platelet transfusions in patients with haematological malignancies undergoing intensive chemotherapy: A pilot study.

Thromboelastometric assessment of the haemostatic effect of tranexamic acid as an adjunct to prophylactic platelet transfusions in patients with haematological malignancies undergoing intensive chemotherapy: A pilot study.

Journal: Vox sanguinis

Published: August 23, 2025

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 13, 2025

Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.

Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.

Journal: Bone marrow transplantation

Published: February 27, 2025

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 17, 2025

Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT.

Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT.

Journal: Bone marrow transplantation

Published: February 11, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026